

# Empire Medicines Limited

Annual Report and Unaudited Financial Statements  
for the Year Ended 31 March 2017

The Moffatts Partnership LLP  
Progress House  
396 Wilmslow Road  
Withington  
Manchester  
M20 3BN

**Empire Medicines Limited**

**Contents**

Company Information	<u>1</u>
Accountants' Report	<u>2</u>
Balance Sheet	<u>3</u> to <u>4</u>
Notes to the Financial Statements	<u>5</u> to <u>8</u>

# **Empire Medicines Limited**

## **Company Information**

<b>Directors</b>	Mr Haroon Mohammad Iqbal Mrs Aysha Saman
<b>Registered office</b>	234 Seymour Grove Old Trafford Manchester Lancashire M16 0DT
<b>Accountants</b>	The Moffatts Partnership LLP Progress House 396 Wilmslow Road Withington Manchester M20 3BN

**Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited  
Statutory Accounts of  
Empire Medicines Limited  
for the Year Ended 31 March 2017**

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Empire Medicines Limited for the year ended 31 March 2017 as set out on pages 3 to 8 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at <http://www.icacw.com/cn/mcmbers/regulations-standards-and-guidance/>.

This report is made solely to the Board of Directors of Empire Medicines Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Empire Medicines Limited and state those matters that we have agreed to state to the Board of Directors of Empire Medicines Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Empire Medicines Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Empire Medicines Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Empire Medicines Limited. You consider that Empire Medicines Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Empire Medicines Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

.....  
The Moffatts Partnership LLP  
Progress House  
396 Wilmslow Road  
Withington  
Manchester  
M20 3BN

21 December 2017

**Empire Medicines Limited**  
**(Registration number: 07581177)**  
**Balance Sheet as at 31 March 2017**

	Note	2017 £	2016 £
<b>Fixed assets</b>			
Tangible assets	<u>4</u>	14,236	16,426
<b>Current assets</b>			
Stocks	<u>5</u>	3,130	3,235
Debtors	<u>6</u>	112,525	115,095
Cash at bank and in hand		<u>103,984</u>	<u>33,815</u>
		219,639	152,145
<b>Creditors: Amounts falling due within one year</b>	<u>7</u>	<u>(190,355)</u>	<u>(138,666)</u>
<b>Net current assets</b>		<u>29,284</u>	<u>13,479</u>
<b>Total assets less current liabilities</b>		43,520	29,905
<b>Provisions for liabilities</b>		<u>(2,847)</u>	<u>(3,285)</u>
<b>Net assets</b>		<u><u>40,673</u></u>	<u><u>26,620</u></u>
<b>Capital and reserves</b>			
Called up share capital		2	1
Profit and loss account		<u>40,671</u>	<u>26,619</u>
Total equity		<u><u>40,673</u></u>	<u><u>26,620</u></u>

For the financial year ending 31 March 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

The notes on pages 5 to 8 form an integral part of these financial statements.  
Page 3

**Empire Medicines Limited**  
**(Registration number: 07581177)**  
**Balance Sheet as at 31 March 2017**

Approved and authorised by the Board on 21 December 2017 and signed on its behalf by:

.....

Mr Haroon Mohammad Iqbal

Director

The notes on pages 5 to 8 form an integral part of these financial statements.  
Page 4

# **Empire Medicines Limited**

## **Notes to the Financial Statements for the Year Ended 31 March 2017**

### **1 General information**

The company is a private company limited by share capital incorporated in United Kingdom.

The address of its registered office is:

234 Seymour Grove Old Trafford

Manchester

Lancashire

M16 0DT

These financial statements were authorised for issue by the Board on 21 December 2017.

### **2 Accounting policies**

#### **Summary of significant accounting policies and key accounting estimates**

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

#### **Statement of compliance**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

#### **Basis of preparation**

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

#### **Tangible assets**

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

#### **Depreciation**

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

<b>Asset class</b>	<b>Depreciation method and rate</b>
Plant & Machinery	25% Reducing balance basis
Fixtures & Fittings	25% Reducing balance basis
Office Equipment	25% Reducing balance basis

#### **Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

# **Empire Medicines Limited**

## **Notes to the Financial Statements for the Year Ended 31 March 2017**

### **Trade debtors**

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

### **Stocks**

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

### **Trade creditors**

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

### **Share capital**

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

### **Dividends**

Dividend distribution to the company's shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

### **3 Staff numbers**

The average number of persons employed by the company (including directors) during the year, was 2 (2016 - 2).



# **Empire Medicines Limited**

## **Notes to the Financial Statements for the Year Ended 31 March 2017**

### **4 Tangible assets**

	<b>Furniture, fittings and equipment £</b>	<b>Other property, plant and equipment £</b>	<b>Total £</b>
<b>Cost or valuation</b>			
At 1 April 2016	12,560	8,000	20,560
Additions	1,250	-	1,250
At 31 March 2017	13,810	8,000	21,810
<b>Depreciation</b>			
At 1 April 2016	2,134	2,000	4,134
Charge for the year	1,940	1,500	3,440
At 31 March 2017	4,074	3,500	7,574
<b>Carrying amount</b>			
At 31 March 2017	9,736	4,500	14,236
At 31 March 2016	10,426	6,000	16,426

### **5 Stocks**

	<b>2017 £</b>	<b>2016 £</b>
Other inventories	3,130	3,235

### **6 Debtors**

	<b>2017 £</b>	<b>2016 £</b>
Trade debtors	48,221	78,410
Other debtors	64,304	36,685
Total current trade and other debtors	112,525	115,095

### **7 Creditors**

	<b>Note</b>	<b>2017 £</b>	<b>2016 £</b>
<b>Due within one year</b>			
Trade creditors		18,212	11,240
Taxation and social security		80	52
Other creditors		172,063	127,374



# **Empire Medicines Limited**

## **Notes to the Financial Statements for the Year Ended 31 March 2017**

### **8 Transition to FRS 102**

These financial statements for the year ended 31st March 2017 are the first financial statements that comply with FRS 102 Section 1A small entities. The date of transition is 1st April 2015.

There has been no impact from the transition to FRS 102.

Page 8

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.